BioNTech SE (22UA) Stock Forecast & Price Target

56 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

22UA Analyst Ratings

Strong Buy

10 Buy

2 Hold

0 Sell

Based on 12 analysts giving stock ratings to

BioNTech

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

22UA Stock 12 Month Forecast

Average Price Target

€107.82

▲(32.70% Upside)

Based on 12 Wall Street analysts offering 12 month price targets for BioNTech SE in the last 3 months. The average price target is €107.82 with a high forecast of €122.90 and a low forecast of €79.62. The average price target represents a 32.70% change from the last price of €81.25.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"76":"€76","123":"€123","87.75":"€87.8","99.5":"€99.5","111.25":"€111.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":122.89531006,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€122.90</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":107.82188294583334,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€107.82</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":79.62231356,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€79.62</span>\n  </div></div>","useHTML":true}}],"tickPositions":[76,87.75,99.5,111.25,123],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,79.05,82.42271615846154,85.79543231692307,89.16814847538461,92.54086463384616,95.9135807923077,99.28629695076923,102.65901310923077,106.0317292676923,109.40444542615384,112.77716158461538,116.14987774307693,119.52259390153846,{"y":122.89531006,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,79.05,81.2632217650641,83.47644353012821,85.6896652951923,87.9028870602564,90.11610882532051,92.32933059038461,94.54255235544872,96.75577412051283,98.96899588557693,101.18221765064104,103.39543941570513,105.60866118076923,{"y":107.82188294583334,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,79.05,79.09402412,79.13804824,79.18207235999999,79.22609648,79.2701206,79.31414472,79.35816883999999,79.40219296,79.44621708,79.4902412,79.53426531999999,79.57828943999999,{"y":79.62231356,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":92.05,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":86.2,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":87.65,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":89.2,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":84.95,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.35,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":93.4,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":93.85,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.65,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.75,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.25,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.5,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.05,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€122.90

Average Price Target€107.82

Lowest Price Target€79.62

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Terence Flynn

Morgan Stanley

€99.53

Buy

22.50%

Upside

Assigned

08/10/26

Morgan Stanley Keeps Their Buy Rating on BioNTech SE (BNTX)

Jessica Fye

J.P. Morgan

€79.62

Hold

-2.00%

Downside

Reiterated

08/06/26

J.P. Morgan Keeps Their Hold Rating on BioNTech SE (BNTX)

Unknown Analyst

Wells Fargo

Not Ranked

Wells Fargo

€121.16

Buy

49.13%

Upside

Reiterated

08/05/26

Wells Fargo Remains a Buy on BioNTech SE (BNTX)

Cory Kasimov

Evercore ISI

€116.84→€112.51

Buy

38.47%

Upside

Reiterated

08/05/26

BioNTech price target lowered to $130 from $135 at Evercore ISIBioNTech price target lowered to $130 from $135 at Evercore ISI

Geoff Meacham

Citi

€112.51→€108.18

Buy

33.15%

Upside

Reiterated

08/05/26

Analysts Offer Insights on Healthcare Companies: Pacira Pharmaceuticals (NASDAQ: PCRX), BioNTech SE (NASDAQ: BNTX) and Henry Schein (NASDAQ: HSIC)

Evan Seigerman

BMO Capital

€110.78

Buy

36.34%

Upside

Reiterated

08/05/26

BMO Capital Remains a Buy on BioNTech SE (BNTX)

Harry Gillis

Berenberg Bank

€121.16→€114.24

Buy

40.60%

Upside

Reiterated

08/05/26

Analysts Are Bullish on Top Healthcare Stocks: BioNTech SE (BNTX), Pfizer (PFE)

John Newman

Canaccord Genuity

€136.74→€122.9

Buy

51.26%

Upside

Assigned

08/05/26

BioNTech price target raised to $142 from $138 at CanaccordBioNTech price target raised to $142 from $138 at Canaccord

Akash Tewari

Jefferies

€119.43

Buy

47.00%

Upside

Reiterated

08/04/26

Jefferies Sticks to Their Buy Rating for BioNTech SE (BNTX)

Tazeen Ahmad

Bank of America Securities

€108.18→€105.59

Buy

29.95%

Upside

Reiterated

08/04/26

BioNTech: New Leadership and Advancing Oncology Pipeline Underpin Buy Rating Despite Lowered Price Target to $122

David Dai

UBS

€116.84

Buy

43.80%

Upside

Reiterated

08/04/26

BioNTech: Oncology Pipeline, Strong Leadership, and Cash Balance Support Buy Rating with Unchanged $135 Price Target

Jeffrey Walch

Bernstein

€83.08

Hold

2.26%

Upside

Reiterated

08/04/26

Bernstein Sticks to Their Hold Rating for BioNTech SE (BNTX)

Yaron Werber

TD Cowen

€81.35

Hold

0.13%

Upside

Reiterated

05/05/26

Analysts Offer Insights on Healthcare Companies: Orthofix Medical (NASDAQ: OFIX), BioNTech SE (NASDAQ: BNTX) and Cogent Biosciences (NASDAQ: COGT)

Asad Haider

Goldman Sachs

€114.24→€115.11

Buy

41.67%

Upside

Reiterated

05/05/26

BioNTech SE (BNTX) Receives a Buy from Goldman Sachs

Robert Burns

H.C. Wainwright

€112.51

Buy

38.47%

Upside

Reiterated

04/27/26

Analyst Reiterates Buy on BioNTech, Maintains $130 Price Target on Strength of Pumitamig Oncology Pipeline

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Terence Flynn

Morgan Stanley

€99.53

Buy

22.50%

Upside

Assigned

08/10/26

Morgan Stanley Keeps Their Buy Rating on BioNTech SE (BNTX)

Jessica Fye

J.P. Morgan

€79.62

Hold

-2.00%

Downside

Reiterated

08/06/26

J.P. Morgan Keeps Their Hold Rating on BioNTech SE (BNTX)

Unknown Analyst

Wells Fargo

Not Ranked

Wells Fargo

€121.16

Buy

49.13%

Upside

Reiterated

08/05/26

Wells Fargo Remains a Buy on BioNTech SE (BNTX)

Cory Kasimov

Evercore ISI

€116.84→€112.51

Buy

38.47%

Upside

Reiterated

08/05/26

BioNTech price target lowered to $130 from $135 at Evercore ISIBioNTech price target lowered to $130 from $135 at Evercore ISI

Geoff Meacham

Citi

€112.51→€108.18

Buy

33.15%

Upside

Reiterated

08/05/26

Analysts Offer Insights on Healthcare Companies: Pacira Pharmaceuticals (NASDAQ: PCRX), BioNTech SE (NASDAQ: BNTX) and Henry Schein (NASDAQ: HSIC)

Evan Seigerman

BMO Capital

€110.78

Buy

36.34%

Upside

Reiterated

08/05/26

BMO Capital Remains a Buy on BioNTech SE (BNTX)

Harry Gillis

Berenberg Bank

€121.16→€114.24

Buy

40.60%

Upside

Reiterated

08/05/26

Analysts Are Bullish on Top Healthcare Stocks: BioNTech SE (BNTX), Pfizer (PFE)

John Newman

Canaccord Genuity

€136.74→€122.9

Buy

51.26%

Upside

Assigned

08/05/26

BioNTech price target raised to $142 from $138 at CanaccordBioNTech price target raised to $142 from $138 at Canaccord

Akash Tewari

Jefferies

€119.43

Buy

47.00%

Upside

Reiterated

08/04/26

Jefferies Sticks to Their Buy Rating for BioNTech SE (BNTX)

Tazeen Ahmad

Bank of America Securities

€108.18→€105.59

Buy

29.95%

Upside

Reiterated

08/04/26

BioNTech: New Leadership and Advancing Oncology Pipeline Underpin Buy Rating Despite Lowered Price Target to $122

David Dai

UBS

€116.84

Buy

43.80%

Upside

Reiterated

08/04/26

BioNTech: Oncology Pipeline, Strong Leadership, and Cash Balance Support Buy Rating with Unchanged $135 Price Target

Jeffrey Walch

Bernstein

€83.08

Hold

2.26%

Upside

Reiterated

08/04/26

Bernstein Sticks to Their Hold Rating for BioNTech SE (BNTX)

Yaron Werber

TD Cowen

€81.35

Hold

0.13%

Upside

Reiterated

05/05/26

Analysts Offer Insights on Healthcare Companies: Orthofix Medical (NASDAQ: OFIX), BioNTech SE (NASDAQ: BNTX) and Cogent Biosciences (NASDAQ: COGT)

Asad Haider

Goldman Sachs

€114.24→€115.11

Buy

41.67%

Upside

Reiterated

05/05/26

BioNTech SE (BNTX) Receives a Buy from Goldman Sachs

Robert Burns

H.C. Wainwright

€112.51

Buy

38.47%

Upside

Reiterated

04/27/26

Analyst Reiterates Buy on BioNTech, Maintains $130 Price Target on Strength of Pumitamig Oncology Pipeline

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

AMLXAmylyx Pharmaceuticals Inc

TNYATenaya Therapeutics

JBIOJade Biosciences

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering BioNTech SE

3 Months

John NewmanCanaccord Genuity

Success Rate

10/14 ratings generated profit

Average Return

+5.29%

Copying John Newman's trades and holding each position for 3 Months would result in 71.43% of your transactions generating a profit, with an average return of +5.29% per trade.

1 Year

Robert BurnsH.C. Wainwright

Success Rate

12/24 ratings generated profit

Average Return

+1.41%

Copying Robert Burns's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +1.41% per trade.

2 Years

Robert BurnsH.C. Wainwright

Success Rate

11/24 ratings generated profit

Average Return

-3.53%

Copying Robert Burns's trades and holding each position for 2 Years would result in 45.83% of your transactions generating a profit, with an average return of -3.53% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

22UA Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 22UA has received 17 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. 22UA average Analyst price target in the past 3 months is 107.82.

Each month's total comprises the sum of three months' worth of ratings.

22UA Financial Forecast

22UA Earnings Forecast

Next quarter’s earnings estimate for 22UA is €0.74 with a range of -€0.02 to €1.36. The previous quarter’s EPS was -€3.24. 22UA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.42% of the time in the same period. In the last calendar year 22UA has Performed in-line its overall industry.

22UA Sales Forecast

Next quarter’s sales forecast for 22UA is €1.06B with a range of €849.00M to €1.21B. The previous quarter’s sales results were €106.26M. 22UA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.03% of the time in the same period. In the last calendar year 22UA has Performed in-line its overall industry.

22UA Stock Forecast FAQ

What is DE:22UA’s average 12-month price target, according to analysts?

Based on analyst ratings, BioNTech SE’s 12-month average price target is 107.82.

What is DE:22UA’s upside potential, based on the analysts’ average price target?

BioNTech SE has 32.70% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is BioNTech SE a Buy, Sell or Hold?

BioNTech SE has a consensus rating of Strong Buy, which is based on 10 buy ratings, 2 hold ratings and 0 sell ratings.

What is BioNTech SE’s share price target?

The average share price target for BioNTech SE is 107.82. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €122.90 ,and the lowest forecast is €79.62. The average share price target represents 32.70% Increase from the current price of €81.25.

What do analysts say about BioNTech SE?

BioNTech SE’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.

How can I buy shares of BioNTech SE?

To buy shares of DE:22UA, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

BioNTech SE (22UA) Stock Forecast & Price Target

22UA Analyst Ratings

22UA Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering BioNTech SE

22UA Analyst Recommendation Trends

22UA Financial Forecast

22UA Earnings Forecast

22UA Sales Forecast

22UA Stock Forecast FAQ

Detailed List of Analyst Forecasts